Gastroenterology Practice Questions

Q: A 45-year-old male with chronic hepatitis C cirrhosis presents with progressive abdominal distension. On examination, he has moderate ascites and mild jaundice. Laboratory investigations show: Serum albumin 2.8 g/dL, Total bilirubin 2.5 mg/dL, INR 1.8, Serum creatinine 0.9 mg/dL, Serum sodium 128 mEq/L. Ascitic fluid analysis reveals: Total protein 1.2 g/dL, SAAG (Serum-Ascites Albumin Gradient) 1.8 g/dL, WBC count 150 cells/mm³ with 70% lymphocytes. What is the Child-Turcotte-Pugh (CTP) score for this patient?

CTP score 10 (Class C). ***CTP score 10 (Class C)*** - The **Child-Turcotte-Pugh (CTP) score** calculation: **Bilirubin 2.5 mg/dL** = 2 points, **Albumin 2.8 g/dL** = 2 points, **INR 1.8** = 2 points, **Moderate ascites** = 3 points, and **No encephalopathy** = 1 point. - Total score of **10 points** (2+2+2+3+1) places the patient in **Class C** (10-15 points), indicating severe decompensated liver disease with poor prognosis. *CTP score 7 (Class B)* - This score underestimates the severity by incorrectly assigning **2 points for moderate ascites** instead of the standard **3 points**. - A score of 7 would indicate **Class B disease** with better functional reserve than this patient actually demonstrates. *CTP score 8 (Class B)* - This calculation also incorrectly assigns **2 points for moderate ascites** when the standard scoring system assigns **3 points**. - The **arithmetic error** leads to underestimation of disease severity and incorrect classification as **Class B**. *CTP score 9 (Class B)* - Still represents an **underestimation** due to incorrect ascites scoring (2 points instead of 3). - While closer to the correct total, it remains in **Class B** rather than the appropriate **Class C** classification for this patient's condition.

Q: A 55-year-old man with type 2 diabetes presents with early satiety, postprandial fullness, and nausea for 6 months. Gastric emptying scintigraphy shows 65% retention at 4 hours (normal <10%). His HbA1c is 9.2%. He takes metformin and glipizide. Endoscopy shows no mechanical obstruction. Which pharmacologic intervention addresses both his gastric dysmotility and glycemic control?

Metoclopramide. ***Metoclopramide*** - It is a **dopamine (D2) antagonist** and **5-HT4 agonist** that serves as the gold standard for **diabetic gastroparesis** by enhancing gastric motility and providing antiemetic effects. - By improving **gastric emptying**, it allows for more predictable absorption of nutrients, which helps align with insulin/medication kinetics to improve overall **glycemic control**. *Domperidone* - While it is an effective **peripheral dopamine antagonist** for gastroparesis, it is often restricted due to risks of **QT prolongation**. - It provides similar prokinetic benefits but is generally used when patients cannot tolerate the **extrapyramidal side effects** of metoclopramide. *Bethanechol* - This is a **muscarinic agonist** that increases the tone of the detrusor muscle and can stimulate GI motility. - It is rarely used for gastroparesis because it lacks the **antiemetic properties** and coordinated motility required for effective management of this condition. *GLP-1 receptor agonist* - These agents, such as liraglutide, are excellent for **glycemic control** but are known to **delay gastric emptying** as a primary mechanism. - Using a GLP-1 agonist in a patient with 65% retention would significantly worsen symptoms of **nausea, bloating, and satiety**. *Erythromycin* - It acts as a **motilin receptor agonist** and is highly potent for acute episodes of severe gastroparesis. - Its long-term utility is severely limited by **tachyphylaxis** (rapidly diminishing response) and potential for **antibiotic resistance**.

Q: A 45-year-old man with chronic pancreatitis presents with steatorrhea and weight loss. Laboratory studies show low fecal elastase. He is started on pancreatic enzyme replacement therapy but continues to have 6-8 greasy stools daily. His medications include omeprazole 40 mg daily for GERD. What is the most appropriate next step in management?

Discontinue proton pump inhibitor. ***Discontinue proton pump inhibitor*** - **Pancreatic lipase** supplements are highly sensitive to pH environments; **PPIs** can elevate gastric pH, which paradoxically interferes with the optimal acidic timing for enzyme activation in some cases or leads to **Small Intestinal Bacterial Overgrowth (SIBO)**. - Prolonged **PPI** use is a risk factor for **SIBO**, a common cause of persistent **steatorrhea** in chronic pancreatitis patients despite adequate enzyme replacement therapy. *Order CT scan of abdomen* - While a **CT scan** can evaluate the structure of the pancreas, it does not address the functional failure of current **enzyme replacement therapy**. - It is generally used for diagnosing **complications** like pseudocysts or malignancy rather than managing refractory **malabsorption**. *Switch to H2-receptor antagonist* - Switching to an **H2-blocker** would still maintain a higher gastric pH and potentially exacerbate **SIBO** or interfere with enzyme kinetics similarly to **PPIs**. - This step does not address the underlying cause of why the **steatorrhea** is persisting despite high-dose therapy. *Add octreotide therapy* - **Octreotide** is used to reduce secretions in conditions like **acromegaly** or secretory diarrhea (e.g., carcinoid syndrome) but can actually worsen **steatorrhea** by inhibiting pancreatic secretion. - It has no role in the routine management of **exocrine pancreatic insufficiency** and would likely be counterproductive. *Increase pancreatic enzyme dosage* - The patient is already symptomatic despite therapy; while increasing the dose is an option, the presence of **PPI** therapy points toward **SIBO** or pH interference as a more likely culprit. - If **steatorrhea** is refractory to standard doses, searching for co-morbidities like **SIBO** or **Giardiasis** is more appropriate than indefinite dose escalation.

Q: Which of the following statements about esophageal varices is true?

Variceal hemorrhage is the most common fatal complication of cirrhosis.. **Explanation:** **Correct Option (C):** Variceal hemorrhage is the **most common fatal complication** of cirrhosis [1]. While ascites is the most common *initial* complication, variceal bleeding carries the highest immediate mortality risk. Approximately 25–40% of patients with cirrhosis will experience a variceal bleed, and it remains a leading cause of death in end-stage liver disease [1]. **Analysis of Incorrect Options:** * **Option A:** Only about **30%** of patients with compensated cirrhosis and **60%** of those with decompensated cirrhosis have varices at the time of diagnosis. They develop at a rate of roughly 5–10% per year. * **Option B:** The mortality rate for an initial episode of variceal bleeding is approximately **15–20%**, not 90%. While high, modern management (octreotide, banding, and antibiotics) has significantly improved survival rates from the historical 50% [1]. * **Option D:** Esophageal varices can occur in the absence of cirrhosis due to **Non-Cirrhotic Portal Hypertension (NCPH)** [1]. Causes include Extrahepatic Portal Venous Obstruction (EHPVO), Non-Cirrhotic Portal Fibrosis (NCPF), or Schistosomiasis. **High-Yield Clinical Pearls for NEET-PG:** * **Predictors of Bleed:** Large size (>5mm), presence of **"Red Color Signs"** (cherry red spots/red wheals) on endoscopy, and Child-Pugh Class C status. * **Prophylaxis:** Non-selective beta-blockers (Propranolol/Nadolol) or Endoscopic Variceal Ligation (EVL) are used for primary prophylaxis. * **Management:** The drug of choice for active bleeding is **Octreotide** or Terlipressin; the definitive procedure of choice is **EVL** [1]. * **Antibiotics:** Prophylactic antibiotics (e.g., Ceftriaxone) are mandatory in variceal bleed to prevent SBP and reduce mortality.

Q: Which of the following is NOT a cause of acute pancreatitis?

Magnetic resonance cholangiopancreatography (MRCP). **Explanation:** The correct answer is **D. Magnetic resonance cholangiopancreatography (MRCP)**. MRCP is a non-invasive diagnostic imaging technique that uses MRI to visualize the biliary and pancreatic ducts. Unlike **ERCP (Endoscopic Retrograde Cholangiopancreatography)**, which involves cannulation of the ampulla and injection of contrast under pressure—a known trigger for post-procedure pancreatitis—MRCP does not involve physical instrumentation of the ducts and therefore **cannot** cause acute pancreatitis. **Analysis of Incorrect Options:** * **A. Hypercalcemia:** High calcium levels lead to the activation of trypsinogen to trypsin within the pancreatic parenchyma and can cause the formation of calcium stones in the ducts, leading to inflammation. * **B. Thrombotic Thrombocytopenic Purpura (TTP):** TTP causes microvascular thrombosis. Ischemia resulting from these microthrombi in the pancreatic vasculature can trigger acute pancreatitis. * **C. Cystic Fibrosis:** This condition leads to thick, inspissated secretions that obstruct the pancreatic ducts, causing premature enzyme activation and chronic/recurrent acute pancreatitis. **Clinical Pearls for NEET-PG:** * **Most Common Cause:** In India and globally, Gallstones (1st) and Alcohol (2nd) are the leading causes. * **Iatrogenic Cause:** ERCP is a high-yield cause of acute pancreatitis (occurring in ~3-5% of cases), whereas MRCP is safe. * **Drug-induced:** Common culprits include Azathioprine, Sulfonamides, Valproate, and Thiazides. * **Scoring:** Remember the **Modified Glasgow** or **Ranson’s Criteria** for predicting severity. * **Investigation of Choice:** **CECT abdomen** (performed after 72 hours) is the gold standard for assessing pancreatic necrosis.

Question 1

A 45-year-old male with chronic hepatitis C cirrhosis presents with progressive abdominal distension. On examination, he has moderate ascites and mild jaundice. Laboratory investigations show: Serum albumin 2.8 g/dL, Total bilirubin 2.5 mg/dL, INR 1.8, Serum creatinine 0.9 mg/dL, Serum sodium 128 mEq/L. Ascitic fluid analysis reveals: Total protein 1.2 g/dL, SAAG (Serum-Ascites Albumin Gradient) 1.8 g/dL, WBC count 150 cells/mm³ with 70% lymphocytes. What is the Child-Turcotte-Pugh (CTP) score for this patient?

Accepted Answer

CTP score 10 (Class C)

Answer

CTP score 7 (Class B)

Answer

CTP score 8 (Class B)

Answer

CTP score 9 (Class B)

Question 2

A 55-year-old man with type 2 diabetes presents with early satiety, postprandial fullness, and nausea for 6 months. Gastric emptying scintigraphy shows 65% retention at 4 hours (normal <10%). His HbA1c is 9.2%. He takes metformin and glipizide. Endoscopy shows no mechanical obstruction. Which pharmacologic intervention addresses both his gastric dysmotility and glycemic control?

Accepted Answer

Metoclopramide

Answer

Domperidone

Answer

Bethanechol

Answer

GLP-1 receptor agonist

Answer

Erythromycin

Question 3

A 45-year-old man with chronic pancreatitis presents with steatorrhea and weight loss. Laboratory studies show low fecal elastase. He is started on pancreatic enzyme replacement therapy but continues to have 6-8 greasy stools daily. His medications include omeprazole 40 mg daily for GERD. What is the most appropriate next step in management?

Accepted Answer

Discontinue proton pump inhibitor

Answer

Order CT scan of abdomen

Answer

Switch to H2-receptor antagonist

Answer

Add octreotide therapy

Answer

Increase pancreatic enzyme dosage

Question 4

Which of the following statements about esophageal varices is true?

Accepted Answer

Variceal hemorrhage is the most common fatal complication of cirrhosis.

Answer

Approximately 90% of cirrhotic patients have varices at the time of diagnosis.

Answer

The mortality rate of bleeding cirrhotic varices is 90%.

Answer

Esophageal varices are not possible in the absence of cirrhosis.

Question 5

Which of the following is NOT a cause of acute pancreatitis?

Accepted Answer

Magnetic resonance cholangiopancreatography (MRCP)

Answer

Hypercalcemia

Answer

Thrombotic thrombocytopenic purpura

Answer

Cystic fibrosis

Gastroenterology — MCQs

Gastroenterology — MCQs

On this page

Practice by Chapter

Want unlimited practice?